Victoria Socha

DocwireNews

Patients with chronic kidney disease (CKD) who develop hyperkalemia are at risk for serious adverse outcomes. The risk is increased when patients with CKD have comorbidities such as diabetes or heart failure. Management of patients with CKD presents challenges related to balancing the cardio- and renoprotective benefits of renin angiotensin aldosterone system (RAAS) blockers with the increased risk of hyperkalemia.Erasmia Sampani, MD, and colleagues at Aristotle University of Thessaloniki, Greece, provided an overview of factors that interfere with serum potassium homeostasis and highlighted newer therapeutic agents available for the treatment of hyperkalemia. The researchers performed a literature search in PubMed/MEDLINE and Scopus from database inception to April 2023.Therapeutic options for the management of hyperkalemia in patients with CKD had been limited to restriction of dietary potassium, correction of metabolic acidosis with bicarbonate solutions, or administration of sodium polystyrene sulfonate; however, those approaches were often problematic and unsuccessful.During the past 10 years, two novel orally administered potassium-exchanging resins, patiromer and sodium zirconium cyclosilicate, have been shown to safely and effectively reduce elevated serum potassium in patients being treated with RAAS blockers. The agents effectively reduce elevated serum potassium and maintain potassium balance within the normal range with excellent tolerability and no serious adverse events.Studies examining the safety and efficacy of new kidney protective therapies such as sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists (MRAs) have shown promising results. SGLT-2 inhibitors and finerenone, a newer MRA, offer additional therapeutic options with a beneficial effect on potassium homeostasis.&ldquo;The combination of these factors is expected to lower the prevalence of hyperkalemia and independently decrease the adverse impact of hyperkalemia on outcomes,&rdquo; the researchers said.Source: <a href="https://www.tandfonline.com/doi/full/10.1080/14656566.2023.2245756" target="_blank" rel="noopener">Expert Opinion on Pharmacotherapy</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Assessing Potassium-Lowering Pharmacotherapy

Hyperkalemia

An overview of factors that interfere with serum potassium homeostasis and highlighted newer therapeutic agents available for the treatment of hyperkalemia. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe